News

6/16/2008
Celator® Pharmaceuticals to Present at 2008 BIO International Convention

6/3/2008
Celator® Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer

5/9/2008
Celator® Pharmaceuticals Announces Appointment of Scott Jackson as CEO

4/16/2008
Celator® Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations

2/5/2008
Celator® Pharmaceuticals to present at 10th Annual BIO CEO and Investor Conference

1/14/2008
Joseph A. Mollica Named Chairman of Celator® Pharmaceuticals Board of Directors

12/10/2007
Celator® Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

11/28/2007
Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator® Pharmaeuticals

10/26/2007
Celator® Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

10/9/2007
Celator Announces Two Additions to Senior Management Team

8/2/2007
Celator Closes $10 Million Follow-On Financing

6/4/2007
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

8/7/2006
Celator Pharmaceuticals Names Dr. Arthur C. Louie as New Chief Medical Officer

7/31/2006
J. Kevin Buchi Joins the Celator Pharmaceuticals Board Of Directors

7/17/2006
Celator Pharmaceuticals Announces Positive European Patent Decision for Combiplex™ Technology Used To Develop Fixed-Ratio Combination Chemotherapies

6/26/2006
Celator Pharmaceuticals Appoints Industry Veteran Felix Botelho as Head of Commercial Development

6/5/2006
Celator Pharmaceuticals Presents Positive Results From Phase I Study For CPX-1 at American Society for Clinical Oncology Meeting

5/3/2005
Celator Pharmaceuticals Closes $40 Million Financing